Novartis Flags Modest 2026 Sales Growth as Major Patent Lapse Looms
Novartis AG expects low single-digit sales growth in 2026 and anticipates a comparable decline in core operating income as the company contends with its largest patent expiry and rising generic competition. The Basel-based group posted full-year 2025 net sales of $54.53 billion, a core operating income of $21.89 billion and confirmed continued inve…